Melissa Baird - May 12, 2025 Form 4 Insider Report for Hims & Hers Health, Inc. (HIMS)

Role
Chief Operating Officer
Signature
/s/ Alexandra Cotter Wilkins, Attorney-in-Fact
Stock symbol
HIMS
Transactions as of
May 12, 2025
Transactions value $
-$1,786,377
Form type
4
Date filed
5/13/2025, 05:07 PM
Previous filing
Apr 23, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Baird Melissa Chief Operating Officer 2269 CHESTNUT STREET, #523, SAN FRANCISCO /s/ Alexandra Cotter Wilkins, Attorney-in-Fact 2025-05-13 0001837815

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HIMS Class A Common Stock Options Exercise $81K +33.3K +4.14% $2.43 838K May 12, 2025 Direct F1
transaction HIMS Class A Common Stock Sale -$758K -13.8K -1.64% $54.98 825K May 12, 2025 Direct F1, F2
transaction HIMS Class A Common Stock Sale -$380K -6.8K -0.82% $55.86 818K May 12, 2025 Direct F1, F3
transaction HIMS Class A Common Stock Sale -$429K -7.56K -0.92% $56.80 810K May 12, 2025 Direct F1, F4
transaction HIMS Class A Common Stock Sale -$300K -5.19K -0.64% $57.87 805K May 12, 2025 Direct F1, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HIMS Stock Option (right to buy) Options Exercise $0 -33.3K -4.58% $0.00 694K May 12, 2025 Class A Common Stock 33.3K $2.43 Direct F1, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The stock option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on November 26, 2024 by the Reporting Person.
F2 Price reported constitutes the average weighted price of shares sold. Shares were sold at varying prices in the range of $54.405 - $55.395. The Reporting Person hereby undertakes, upon request of the Commission, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F3 Price reported constitutes the average weighted price of shares sold. Shares were sold at varying prices in the range of $55.405 - $56.315. The Reporting Person hereby undertakes, upon request of the Commission, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F4 Price reported constitutes the average weighted price of shares sold. Shares were sold at varying prices in the range of $56.425 - $57.32. The Reporting Person hereby undertakes, upon request of the Commission, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F5 Price reported constitutes the average weighted price of shares sold. Shares were sold at varying prices in the range of $57.45 - $58.265. The Reporting Person hereby undertakes, upon request of the Commission, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F6 Prior to the Company's business combination transaction in 2021, the option represented the right to purchase 1,719,884 shares of Hims, Inc., with an exercise price of $1.10. Following the Company's business combination transaction in 2021, the option converted into the right to purchase 779,073 shares of the Company with an exercise price of $1.75. 100% of the shares subject to the option have vested.